Takeaway

• A single intramuscular injection of 2 monoclonal antibodies, tixagevimab and cilgavimab, reduces the risk of progression to severe COVID-19 or death from any cause by 50.5% when administered in the early outpatient setting.
• Participants in this phase 3 trial were adults with mild to moderate COVID-19 who were considered...